Bangwei Cao Selected Research

apatinib

1/2021	Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
4/2020	Addition of docosahexaenoic acid synergistically enhances the efficacy of apatinib for triple-negative breast cancer therapy.
1/2020	Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways.
1/2019	Pyrotinib treatment on HER2-positive gastric cancer cells promotes the released exosomes to enhance endothelial cell progression, which can be counteracted by apatinib.
7/2018	The coordinated effects of Apatinib and Tripterine on the proliferation, invasiveness and apoptosis of human hepatoma Hep3B cells.
5/2018	Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells.
4/2018	Astragalus polysaccharide enhanced antitumor effects of Apatinib in gastric cancer AGS cells by inhibiting AKT signalling pathway.
1/2018	Traditional Chinese medicine Astragalus polysaccharide enhanced antitumor effects of the angiogenesis inhibitor apatinib in pancreatic cancer cells on proliferation, invasiveness, and apoptosis.
1/2018	VEGFR-2 Inhibitor Apatinib Hinders Endothelial Cells Progression Triggered by Irradiated Gastric Cancer Cells-derived Exosomes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bangwei Cao Research Topics

Disease

39	Neoplasms (Cancer) 01/2022 - 07/2005
10	Stomach Neoplasms (Stomach Cancer) 10/2021 - 02/2005
9	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2022 - 07/2015
8	Neoplasm Metastasis (Metastasis) 05/2021 - 05/2015
7	Colonic Neoplasms (Colon Cancer) 01/2021 - 01/2017
6	Breast Neoplasms (Breast Cancer) 11/2021 - 10/2015
5	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 05/2016
5	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 05/2018
5	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 01/2014
4	Adenocarcinoma 11/2021 - 01/2014
3	Carcinoma (Carcinomatosis) 01/2021 - 07/2005
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020 - 05/2015
3	Neutropenia 05/2016 - 07/2015
2	Digestive System Neoplasms (Cancer of the Digestive System) 01/2022 - 01/2021
2	Leukopenia 01/2021 - 07/2015
2	Triple Negative Breast Neoplasms 01/2021 - 04/2020
2	Hand-Foot Syndrome 01/2021 - 05/2016
2	Hepatitis B 01/2021 - 11/2006
2	Anemia 01/2021 - 01/2015
2	Esophageal Squamous Cell Carcinoma 01/2020 - 01/2013
2	Fatigue 05/2016 - 01/2015
2	Carcinogenesis 01/2015 - 01/2013
2	Lung Neoplasms (Lung Cancer) 01/2015 - 05/2012
2	Infections 01/2013 - 09/2007
1	Blister (Bulla) 01/2021
1	Lymphoma (Lymphomas) 01/2021
1	Cardiomyopathies (Cardiomyopathy) 01/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Adenoma (Adenomas) 01/2020
1	Diarrhea 01/2020
1	Esophageal Neoplasms (Esophageal Cancer) 01/2020
1	Disease Progression 12/2019
1	Yin Deficiency (Yinxu) 01/2019

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 10/2021 - 01/2013
9	apatinibIBA 01/2021 - 01/2018
7	ErbB Receptors (EGF Receptor)IBA 12/2019 - 01/2015
5	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 07/2018 - 01/2018
4	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2020
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2018
4	MicroRNAs (MicroRNA)IBA 01/2020 - 01/2015
4	Tyrosine Kinase InhibitorsIBA 01/2019 - 01/2015
3	CateninsIBA 05/2021 - 08/2015
3	AutoantibodiesIBA 01/2021 - 05/2015
3	AntigensIBA 01/2021 - 05/2015
3	Bevacizumab (Avastin)FDA Link 12/2019 - 10/2015
3	Codon (Codons)IBA 05/2012 - 07/2005
2	Cisplatin (Platino)FDA LinkGeneric 03/2022 - 07/2015
2	Cadherins (E-Cadherin)IBA 05/2021 - 08/2015
2	VimentinIBA 05/2021 - 08/2015
2	Conditioned Culture MediaIBA 01/2021 - 01/2020
2	Long Noncoding RNAIBA 01/2021 - 01/2020
2	AntibodiesIBA 01/2021 - 08/2017
2	Monoclonal AntibodiesIBA 01/2021 - 12/2019
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2020
2	Angiogenesis InhibitorsIBA 04/2020 - 01/2018
2	pyrotinibIBA 01/2020 - 01/2019
2	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 01/2014
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2019 - 01/2018
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2019 - 10/2015
2	Carboplatin (JM8)FDA LinkGeneric 12/2019 - 07/2015
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2018 - 07/2015
2	Lysine (L-Lysine)FDA Link 11/2018 - 07/2005
2	Polysaccharides (Glycans)IBA 04/2018 - 01/2018
2	Claudin-3IBA 01/2018 - 08/2015
2	Transcription Factors (Transcription Factor)IBA 01/2018 - 05/2015
2	ORALIT (ORS)IBA 05/2015 - 12/2010
2	Gemcitabine FDA Link 07/2014 - 01/2014
2	DNA (Deoxyribonucleic Acid)IBA 05/2012 - 07/2005
1	GlobulinsIBA 01/2022
1	AlbuminsIBA 01/2022
1	spleen aminopeptide oral lyophilized powderIBA 11/2021
1	sintilimabIBA 11/2021
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2021
1	Alanine (L-Alanine)FDA Link 01/2021
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2021
1	BilirubinIBA 01/2021
1	Transaminases (Aminotransferases)IBA 01/2021
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2021
1	Sorafenib (BAY 43-9006)FDA Link 01/2021
1	centromere protein FIBA 01/2021
1	zimberelimabIBA 01/2021
1	Docosahexaenoic AcidsIBA 04/2020
1	Calcibiotic Root Canal SealerIBA 01/2020
1	IpilimumabIBA 01/2020
1	Leucine (L-Leucine)FDA Link 01/2020
1	raltitrexed (D 1694)IBA 01/2020
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2020
1	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 01/2020
1	ProteomeIBA 01/2020
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2020
1	Growth Differentiation Factor 15IBA 01/2020
1	Biosimilar PharmaceuticalsIBA 12/2019
1	tianfoshenIBA 01/2019
1	human ERBB2 proteinIBA 01/2019
1	Phenobarbital (Luminal)FDA Link 11/2018
1	histone H3 trimethyl Lys4IBA 11/2018

Therapy/Procedure

18	Drug Therapy (Chemotherapy) 03/2022 - 01/2014
15	Therapeutics 01/2022 - 01/2014
4	Radiotherapy 01/2021 - 05/2016
1	Immunotherapy 01/2022